SFES (Safeguard Scientifics) Cash And Cash Equivalents : $9.50 Mil (As of Dec. 2023)

View and export this data going back to 1971. Start your Free Trial

What is Safeguard Scientifics Cash And Cash Equivalents?

Safeguard Scientifics's quarterly cash and cash equivalents increased from Jun. 2023 ($14.25 Mil) to Sep. 2023 ($15.66 Mil) but then stayed the same from Sep. 2023 ($15.66 Mil) to Dec. 2023 ($9.50 Mil).

Safeguard Scientifics's annual cash and cash equivalents declined from Dec. 2021 ($24.74 Mil) to Dec. 2022 ($13.33 Mil) and declined from Dec. 2022 ($13.33 Mil) to Dec. 2023 ($9.50 Mil).

Safeguard Scientifics Cash And Cash Equivalents Historical Data

The historical data trend for Safeguard Scientifics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Safeguard Scientifics Cash And Cash Equivalents Chart

Safeguard Scientifics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

25.03

15.60

24.74

13.33

9.50

Safeguard Scientifics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															13.33	11.01	14.25	15.66	9.50

Safeguard Scientifics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Safeguard Scientifics (OTCPK:SFES) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Safeguard Scientifics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Safeguard Scientifics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Safeguard Scientifics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » Safeguard Scientifics Inc (OTCPK:SFES) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

150 N. Radnor Chester Road, Suite F-200, Radnor, PA, USA, 19087

Website

https://www.safeguard.com

Safeguard Scientifics Inc is engaged in the development of early- and growth-stage businesses by providing capital and relevant expertise to fuel the growth of an attractive portfolio of technology-enabled healthcare, digital media, and other companies. It generally promotes the growth and development of these companies through Board representation and minority equity ownership. In addition to supporting the companies, it focuses on pursuing monetization opportunities to return value to shareholders.

Executives

Satterfield Thomas A Jr	10 percent owner	2609 CALDWELL MILL LN, BIRMINGHAM AL 35243
Beth Michelson	director	C/O CARTESIAN GROWTH CORPORATION II, 505 FIFTH AVENUE, 15TH FLOOR, NEW YORK NY 10017
Ross D Demont	director	51 PICKWICK ROAD, NEWTON MA 02465
Manko Joseph M. Jr.	director	1717 ARCH STREET, 37TH FLOOR, PHILADELPHIA PA 19103
Bob Rosenthal	director	20 NEWBURY ST, BOSTON MA 02116
Mark Herndon	officer: SVP & Chief Financial Officer	C/O SAFEGUARD SCIENTIFICS, INC., 170 N. RADNOR-CHESTER ROAD, SUITE 200, RADNOR PA 19087
Eric Salzman	officer: Chief Restructuring Officer	C/O 8X8 INC., 675 CREEKSIDE WAY, CAMPCALL CA 95008
Ira M Lubert	director	C/O PENN. REAL ESTATE INVESTMENT TRUST, 200 S. BROAD ST., THE BELLEVUE, PHILADEPHIA PA 19102
John Joseph Roberts	director	1007 CANTERBURY LANE, VILLANOVA PA 19085
Brian J Sisko	officer: Senior V.P. & General Counsel	435 DEVON PARK DRIVE, BUILDING 800, WAYNE PA 19087
Russell D Glass	director	170 N. RADNOR-CHESTER ROAD, SUITE 200, RADNOR PA 19087
David A Kille	officer: Senior VP & CFO	C/O SAFEGUARD SCIENTIFICS, INC., 170 N. RADNOR-CHESTER ROAD, SUITE 200, RADNOR PA 19087
Maureen F Morrison	director	C/O ASBURY AUTOMOTIVE GROUP, 2905 PREMIERE PKWY, STE 300, DULUTH GA 30097
Stephen T Zarrilli	officer: Acting Sr VP & Acting CFO	FIBERLINK COMMUNICATIONS CORP., 794 PENLLYN PIKE, BLUE BELL PA 19422
Andrew E Lietz	director	P O BOX 738, RYE NH 03870